2021
Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome
Samadder N, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, Kunze K, Golafshar M, Uson P, Mountjoy L, Ertz-Archambault N, Patel N, Rodriguez E, Lizaola-Mayo B, Lehrer M, Thorpe C, Yu N, Esplin E, Nussbaum R, Sharp R, Azevedo C, Klint M, Hager M, Macklin-Mantia S, Bryce A, Bekaii-Saab T, Sekulic A, Stewart A. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. JAMA Oncology 2021, 7: 230-237. PMID: 33126242, PMCID: PMC7600058, DOI: 10.1001/jamaoncol.2020.6252.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesGenetic Predisposition to DiseaseGenetic TestingGerm-Line MutationHumansMaleNeoplastic Syndromes, HereditaryProspective StudiesConceptsPrevalence of pathogenic germline variantsFamily variant testingPathogenic germline variantsSolid tumor cancersHigh-penetrance cancer susceptibility genesFamily history of cancerMayo Clinic Cancer CenterRisk-reducing interventionsUniversal genetic testingMultigene panel testingHigh-penetrance variantsHistory of cancerClinic Cancer CenterUniversal testing approachGermline variantsGuideline-directed approachYounger age of diagnosisTumor cancersCancer susceptibility genesClinically actionable findingsTargeted testingCancer screeningAge of diagnosisGermline testingVariant testing
2019
Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study
Hruska CB, Hunt KN, Conners AL, Geske JR, Brandt KR, Degnim AC, Vachon CM, O’Connor M, Rhodes DJ. Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. Breast Cancer Research 2019, 21: 38. PMID: 30850011, PMCID: PMC6408779, DOI: 10.1186/s13058-019-1120-5.Peer-Reviewed Original ResearchConceptsLow-dose tamoxifenMolecular breast imagingBackground parenchymal uptakeOral tamoxifenParenchymal uptakeBreast cancer risk reductionBreast cancer risk factorsEffectiveness of tamoxifenCancer risk factorsCancer risk reductionBreast cancer historyShort-term interventionMean ageCancer historyRisk factorsBreast fibroglandular tissueTamoxifenMolecular breastAverage countStudy participantsSubcutaneous fatPilot studyWomenT-testIntervention
2015
Effect of Menstrual Cycle Phase on Background Parenchymal Uptake at Molecular Breast Imaging
Hruska CB, Conners AL, Vachon CM, O'Connor MK, Shuster LT, Bartley AC, Rhodes DJ. Effect of Menstrual Cycle Phase on Background Parenchymal Uptake at Molecular Breast Imaging. Academic Radiology 2015, 22: 1147-1156. PMID: 26112057, PMCID: PMC4532620, DOI: 10.1016/j.acra.2015.04.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultBreastBreast DensityChromatography, LiquidCohort StudiesEstradiolEstroneFemaleFollicle Stimulating HormoneFollicular PhaseHumansLuteal PhaseMammographyMiddle AgedMolecular ImagingPremenopauseProgesteroneProspective StudiesRadiopharmaceuticalsSex Hormone-Binding GlobulinTandem Mass SpectrometryTechnetium Tc 99m SestamibiTestosteroneConceptsBackground parenchymal uptakeMolecular breast imagingMenstrual cycle phaseLuteal phaseMenstrual cycleNondense breastsFollicular phaseHormone levelsParenchymal uptakeDense breastsExogenous hormone useRegular menstrual cyclesLevels of TCCycle phaseNormal fibroglandular tissuePremenopausal volunteersPremenopausal womenHormone useSpearman correlation coefficientBreast imagingStudy radiologistsMammographic densityBreastFibroglandular tissueWomenJournal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts.
Rhodes DJ, Hruska CB, Conners AL, Tortorelli CL, Maxwell RW, Jones KN, Toledano AY, O'Connor MK. Journal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. American Journal Of Roentgenology 2015, 204: 241-51. PMID: 25615744, PMCID: PMC4423604, DOI: 10.2214/ajr.14.13357.Peer-Reviewed Original ResearchConceptsCancer detection rateMolecular breast imagingDense breastsOverall cancer detection rateInvasive cancer detection rateDetection ratePositive predictive valueRadiation dose reductionAsymptomatic womenBilateral cancerDCIS detectionSupplemental screeningInvasive diseaseBiopsy rateDose reductionReduced radiation dosePredictive valueMolecular breastBreastScreening mammographyDiagnostic performanceRadiopharmaceutical activityCancerRadiation doseMammography
2010
Dedicated Dual-Head Gamma Imaging for Breast Cancer Screening in Women with Mammographically Dense Breasts
Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK. Dedicated Dual-Head Gamma Imaging for Breast Cancer Screening in Women with Mammographically Dense Breasts. Radiology 2010, 258: 106-18. PMID: 21045179, DOI: 10.1148/radiol.10100625.Peer-Reviewed Original ResearchConceptsPositive predictive valueBreast cancerDense breastsDiagnostic yieldNode-negative breast cancerAdditional risk factorsNumber of patientsGamma imagingNumber of biopsiesBreast cancer screeningHIPAA-compliant protocolIpsilateral cancerAbnormal findingsAsymptomatic womenEligible participantsCancer screeningRisk factorsSestamibi injection